Lixte Biotechnology Holdings

LIXT40

Penny Stock

$1.63arrow_drop_up7.23%$0.10

Penny Stock

LIXT40

$1.63

arrow_drop_up7.23%$0.10

Penny Stock

Performance History

Key Stats
Open	$1.59
Prev. Close	$1.52
EPS	-1.73
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$3.66M
PE Ratio	-

	LOW	HIGH
Day Range	1.52	1.77
52 Week Range	1.27	4.42

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-1.73

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Lixte Biotechnology Holdings (LIXT)

Lixte Biotechnology Holdings, Inc. (LIXT) is a biotechnology company that focuses on the discovery and development of drugs to treat cancer and other serious diseases. The company's primary drug candidate, LB-100, is a small molecule inhibitor of protein phosphatase 2A (PP2A), an enzyme that plays a key role in the regulation of cell growth and survival. By inhibiting PP2A, LB-100 has the potential to disrupt the growth of cancer cells and enhance the effectiveness of existing cancer therapies.

Lixte Biotechnology has made significant progress in the development of LB-100, with multiple clinical trials currently underway. The company has completed phase 1 studies in patients with solid tumors, acute myeloid leukemia, and myelodysplastic syndrome, demonstrating the safety and tolerability of LB-100. Phase 2 trials are ongoing, evaluating LB-100 in combination with other standard-of-care therapies for various types of cancer.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Dr. John S. Kovach M.D.
Headquarters: Pasadena
Employees: 3
Exchange: NASDAQ

add Lixte Biotechnology Holdings to watchlist

Keep an eye on Lixte Biotechnology Holdings

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Lixte Biotechnology Holdings's (LIXT) price per share?

The current price per share for Lixte Biotechnology Holdings (LIXT) is $1.64. The stock has seen a price change of $0.11 recently, indicating a 7.24% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Lixte Biotechnology Holdings (LIXT)?

For Lixte Biotechnology Holdings (LIXT), the 52-week high is $4.42, which is 170.17% from the current price. The 52-week low is $1.27, the current price is 28.31% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Lixte Biotechnology Holdings (LIXT) a growth stock?

Lixte Biotechnology Holdings (LIXT) has shown an average price growth of -4.13% over the past three years. It has received a score of 3 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Lixte Biotechnology Holdings as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Lixte Biotechnology Holdings (LIXT) stock price performance year to date (YTD)?

As of the latest data, Lixte Biotechnology Holdings (LIXT) has a year-to-date price change of -28.56%. Over the past month, the stock has experienced a price change of -18.2%. Over the last three months, the change has been -9.11%. Over the past six months, the figure is -32.67%.

help

Is Lixte Biotechnology Holdings (LIXT) a profitable company?

Lixte Biotechnology Holdings (LIXT) has a net income of -$5.09M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$5.09M. Furthermore, the EBITDA is $0.

help

What is the market capitalization of Lixte Biotechnology Holdings (LIXT)?

Lixte Biotechnology Holdings (LIXT) has a market capitalization of $3.67M. The average daily trading volume is 1.65, indicating the stock's liquidity and investor engagement.

News

PRESS RELEASES

Jun 14, 2024

LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical Trial

PRESS RELEASES

Jun 14, 2024

LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon Cancer Clinical Trial

PRESS RELEASES

Jun 6, 2024

Scientific Journal Reports Findings that Show LIXTE’s Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System

PRESS RELEASES

Jun 3, 2024

LIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical Officer

PRESS RELEASES

May 8, 2024

LIXTE Biotechnology Co-Sponsoring International Scientific Conference on “Therapeutic Over-Activation in Cancer”